You will notice that psoriasis and psoriatic arthritis are closely connected conditions, and they are often discussed together at major dermatology and rheumatology conferences. These international meetings give specialists the chance to share research, review treatment advances, and explore ways to improve care for both your skin and joint symptoms. This joined-up focus helps you understand both conditions as part of the same overall disease process. As a result, care is becoming more coordinated across specialties.
You will also hear that, in recent years, conference sessions have placed more emphasis on how psoriasis and psoriatic arthritis overlap. Researchers now recognise that many people with psoriasis may also experience joint involvement, even if symptoms are initially mild. Because of this, dermatologists and rheumatologists are increasingly working together more closely. This collaboration helps ensure your condition is assessed more thoroughly and managed in a more balanced way.
For you as a patient, these discussions are important because they directly influence how doctors diagnose, monitor, and treat both skin and joint symptoms in everyday practice. Many of the approaches used in clinics today have been shaped by findings first shared at international conferences. One of the strongest messages from recent meetings is the importance of recognising psoriatic arthritis early. You will often hear experts stressing that joint symptoms should never be ignored, as early detection can make a real difference to your long-term outcomes.
The Link Between Psoriasis and Psoriatic Arthritis
You will notice that one of the most common topics at conferences is the close link between psoriasis and psoriatic arthritis. While psoriasis mainly affects your skin, psoriatic arthritis involves inflammation in your joints and the tissues around them. These two conditions are closely connected, even though they can affect different parts of your body. As a result, they are often discussed together in both dermatology and rheumatology sessions.
You will also hear that researchers are still trying to understand why some people with psoriasis go on to develop joint disease while others do not. This is an important area of study because it may help improve how early signs are recognised in you. By identifying patterns and risk factors more clearly, specialists hope to diagnose psoriatic arthritis at an earlier stage. This could lead to more timely and effective treatment.
Conference presentations often highlight that these conditions should be viewed as part of the same disease spectrum rather than completely separate problems. This broader understanding helps improve how your condition is assessed and managed in clinical practice. It also encourages better collaboration between different specialists involved in your care. Ultimately, this approach supports more joined-up and effective treatment for you.
Early Detection Remains a Major Priority
You will notice that international conference speakers consistently emphasise the importance of identifying psoriatic arthritis as early as possible. If diagnosis is delayed, there is a higher risk of long-term joint damage developing over time. This is why early recognition is seen as such a key part of managing your condition effectively. As a result, it remains a major priority in both dermatology and rheumatology discussions.
You will also hear that researchers are actively working to identify early warning signs before significant joint problems appear. This includes looking at subtle symptoms that may develop before clear joint damage is visible. By improving awareness of these early indicators, specialists hope to diagnose psoriatic arthritis at a much earlier stage in your care. This can make treatment more effective and help protect long-term joint function.
Conference discussions often encourage dermatologists to ask you about symptoms such as stiffness, swelling, or joint pain during routine psoriasis appointments. These simple questions can help detect early signs that might otherwise be missed. Earlier recognition allows for faster referral to a specialist when needed. Ultimately, this leads to more timely treatment and better long-term outcomes for you.
Joint Symptoms Can Appear Before Diagnosis
When you attend dermatology and rheumatology conferences, you will often hear that joint symptoms can develop slowly and may be easy to miss at first in conditions like Psoriasis. You might notice mild stiffness, aching, or slight swelling without immediately realising that these changes could be significant. Because the symptoms can be subtle, diagnosis is sometimes delayed.
- Early symptoms can be mild and easy to overlook: You may experience small changes such as morning stiffness, general joint discomfort, or occasional swelling. These symptoms can come and go, which makes them easy to dismiss or attribute to other causes like fatigue or minor strain.
- Importance of recognising subtle warning signs: Conference discussions often highlight the need to pay attention to early joint changes. If you notice persistent stiffness or recurring discomfort, it may be worth discussing with a healthcare professional, as early signs can be important for diagnosis.
- Ongoing research into early detection: Researchers are actively working on ways to identify these early symptoms more reliably. The goal is to improve screening and help clinicians recognise inflammatory joint involvement sooner, before it becomes more advanced.
- Early intervention can improve outcomes: You will often hear that starting treatment earlier may help reduce long-term joint damage and improve overall quality of life. This is why timely recognition and diagnosis are considered so important.
- Increased awareness among patients and clinicians: Conferences aim to improve awareness on both sides. When you understand what early symptoms look like, you are more likely to seek help sooner, and clinicians are better equipped to investigate and diagnose early.
Overall, recognising that joint symptoms can appear before a formal diagnosis helps support earlier intervention and better long-term management.
Collaboration Between Specialists Is Increasing
You will notice that a major theme at international conferences is the growing collaboration between dermatologists and rheumatologists. Because psoriasis and psoriatic arthritis affect different parts of your body, your care often benefits when these specialists work together. This joined-up approach helps ensure that both your skin and joint symptoms are properly considered. As a result, care is becoming more coordinated and patient-focused.
You will also hear that conference sessions frequently explore how specialists can communicate and collaborate more effectively. This includes sharing information about your symptoms, test results, and treatment progress. By working more closely together, doctors can improve both diagnosis and long-term treatment planning for you. This helps reduce the risk of important symptoms being overlooked.
This collaborative model supports a more integrated approach to your care. You will see that it allows both skin and joint issues to be managed in a more balanced and comprehensive way. It also helps ensure that treatment decisions are made with input from all relevant specialists. Ultimately, this trend towards integrated care continues to grow and improve outcomes for you.
Biologic Therapies Are Frequently Discussed
You will notice that biologic therapies remain one of the most important topics at psoriasis and psoriatic arthritis sessions. These treatments are regularly discussed at conferences because they target specific inflammatory pathways involved in both your skin and joint disease. This more precise approach has significantly changed how moderate to severe psoriasis is managed. As a result, biologics are now considered a key part of modern treatment strategies.
You will also hear researchers presenting data on how these therapies perform in terms of plaque clearance, joint symptom improvement, and long-term disease control. This includes detailed discussions about how well they help reduce inflammation in different patient groups. By studying these outcomes, specialists can better understand which treatments may work best for your individual condition. This helps support more informed and effective treatment decisions.
Conference discussions often highlight how biologic therapies have transformed treatment options for many patients. You will see that they are now widely used because of their ability to target the underlying disease process rather than just the symptoms. This has led to better control of both skin and joint manifestations for many people. Ultimately, biologic therapies continue to play a central role in modern management approaches for you.
Inflammation Remains a Core Research Topic
You will notice that inflammation remains one of the most important topics discussed at psoriasis and psoriatic arthritis conferences. It plays a central role in both your skin symptoms and joint involvement. Researchers continue to study the immune pathways that trigger and maintain this inflammatory response in your body. This helps improve overall understanding of how the disease develops and progresses.
You will also hear that understanding these inflammatory mechanisms is essential for identifying better treatment targets. By mapping out how the immune system behaves, scientists can develop therapies that are more precise and effective for you. This includes looking at how inflammation affects different tissues, such as your skin, joints, and surrounding structures. These insights help explain why symptoms can vary so much between individuals.
Conference presentations often explore how ongoing inflammation contributes directly to the symptoms you experience. This includes redness, swelling, pain, and stiffness, depending on the areas affected. By studying these processes in detail, researchers can refine existing treatments and support the development of new ones. Ultimately, the better inflammation is understood, the more targeted and effective future treatments are likely to become for you.
Personalised Treatment Is Becoming More Common
You will notice that personalised medicine is a recurring and growing theme at international psoriasis and psoriatic arthritis conferences. Specialists are increasingly recognising that each patient responds differently to treatment, even when the diagnosis is the same. This means your care may not follow a one-size-fits-all approach. Instead, it is becoming more tailored to your individual needs and circumstances.
You will also hear that several factors can influence treatment decisions, including how severe your disease is, whether your joints are involved, your lifestyle, and your medical history. All of these elements help doctors decide which treatment is most suitable for you. Researchers are continuing to study how different therapies perform in different patient groups. This helps improve the accuracy of treatment selection and supports better outcomes.
The aim of this personalised approach is to improve your results while reducing unnecessary changes in treatment over time. When therapy is better matched to your specific situation, it is more likely to be effective and sustainable. You will see that this also helps avoid repeated trial-and-error adjustments. Ultimately, personalisation is expected to become even more important in your future care.
Quality of Life Is Receiving Greater Attention
You will notice that conference presentations are increasingly focusing on how psoriasis and psoriatic arthritis affect your quality of life. Researchers now recognise that these conditions can influence far more than just your skin or joints. They may also affect your confidence, mobility, work life, and emotional wellbeing. As a result, the impact is being understood in a much broader and more holistic way.
You will also hear that patients can experience challenges that go beyond visible symptoms or joint pain. For example, you may find that daily activities, social situations, or even your mood are affected at times. These wider effects are now considered an important part of understanding the full burden of the condition. This helps specialists see the real-life impact on you, not just the clinical signs.
This broader understanding is helping to shape more patient-centred approaches to treatment. You will see that improving your overall wellbeing is becoming just as important as controlling physical symptoms. Because of this, quality-of-life measures are now regularly included in research and clinical discussions. Ultimately, this ensures that treatment success is measured in a way that reflects what truly matters to you.
Fatigue Is Being Studied More Closely
You will notice that fatigue is increasingly being recognised as an important symptom at psoriasis and psoriatic arthritis conferences. It is often discussed because it can have a significant impact on your daily life, even though it is sometimes less visible than skin or joint symptoms. Researchers are paying closer attention to how common fatigue is in people living with inflammatory conditions like yours. This helps build a clearer picture of the full disease burden.
You will also hear that presentations often explore how fatigue may be linked to inflammation, sleep quality, and your overall energy levels. These factors can interact in complex ways, making fatigue feel more persistent or difficult to manage. By understanding these relationships better, specialists hope to identify more effective ways of supporting you. This includes looking at both medical and lifestyle-related contributors.
This growing focus reflects a broader shift towards treating you as a whole person rather than focusing only on individual symptoms. You will see that improving fatigue is becoming an important part of overall treatment goals. It is no longer viewed as a secondary concern but as a key factor in your quality of life. Ultimately, this approach supports more comprehensive and patient-centred care for you.
Imaging Technologies Are Improving Diagnosis
When you attend international dermatology and rheumatology meetings, you will notice that imaging technology is becoming an increasingly important topic, especially in conditions like Psoriasis. Advanced tools are helping clinicians detect changes earlier and understand what is happening beneath the surface of the skin and joints. This can make a real difference in how quickly and accurately a diagnosis is made.
- Growing use of advanced imaging techniques: You will often hear about ultrasound and other imaging methods being used to look more closely at joints and surrounding tissues. These tools allow clinicians to see inflammation that may not be obvious during a physical examination.
- Helping identify early joint inflammation: One of the key areas of research is how imaging can detect subtle early changes. If you are developing joint involvement, these technologies may help identify it sooner, even before symptoms become more severe or obvious.
- Improving diagnostic accuracy and monitoring: Conferences often highlight how imaging can support more precise diagnosis and better monitoring of treatment response. This helps your clinician understand whether a therapy is working effectively or needs adjustment.
- Supporting earlier detection in selected patients: In some cases, imaging may help identify early signs of psoriatic arthritis before significant joint damage occurs. This can be especially useful if you are at higher risk or already have skin symptoms.
- Better long-term management outcomes: When changes are detected earlier and more accurately, treatment can be started sooner. This may help improve long-term outcomes and reduce the risk of ongoing joint damage.
Overall, advances in imaging technology are making diagnosis more precise and proactive. For you, this means a greater chance of earlier detection and more effective long-term management of inflammatory conditions.
Long-Term Safety Data Remains Important
You will notice that long-term safety is a major research priority at psoriasis and psoriatic arthritis conferences. Because many treatments are used for years rather than just a short period, specialists need to understand how they perform over extended use. This helps ensure that the therapies you receive remain safe and effective in the long run. As a result, safety continues to be a central focus in all major discussions.
You will also hear conference presentations reviewing long-term safety data from biologics and other targeted therapies. These studies often track patients over several years to see how treatments affect overall health, disease control, and any potential side effects. This long-term evidence is especially important when making treatment decisions for you. It helps doctors feel more confident about recommending therapies that are both effective and sustainable.
This growing body of safety data supports more informed and careful treatment planning. You will see that specialists use this information to balance effectiveness with long-term risk. It also helps guide decisions about continuing, adjusting, or switching treatments when needed. Ultimately, ongoing safety discussions remain a key part of ensuring your care is both reliable and well-supported by evidence.
Real-World Evidence Is Influencing Practice
You will notice that real-world evidence is becoming increasingly important at international psoriasis and psoriatic arthritis conferences. These studies look at how treatments perform in everyday clinical practice, rather than in highly controlled research settings. This gives you a more practical picture of how therapies work once they are used in routine care. As a result, it helps bridge the gap between research and real-life experience.
You will also hear researchers presenting data on factors such as patient satisfaction, treatment persistence, and day-to-day outcomes. This includes information on how well treatments are tolerated over time and whether patients continue with them long term. These insights are valuable because they reflect what actually happens in your real treatment journey. They also help specialists understand how treatments perform outside of clinical trial conditions.
Real-world evidence is often used alongside clinical trial results to give a more complete understanding of treatment effectiveness. You will see that combining both types of data helps doctors make better-informed decisions for your care. It ensures that recommendations are based not only on ideal study conditions but also on practical experience. Ultimately, this type of evidence is especially important for guiding long-term management of your condition.
Difficult-to-Treat Patients Are Receiving More Focus
You will notice that conference speakers are increasingly focusing on patients with more complex or difficult-to-treat forms of psoriasis and psoriatic arthritis. These may include situations where you experience both significant skin involvement and noticeable joint symptoms at the same time. This can make management more challenging, so it often requires a more tailored and specialist approach. As a result, these patients are now a key focus in research discussions.
You will also hear that researchers are actively exploring ways to improve outcomes for people in these more complex situations. This includes studying how different treatments perform when disease severity is higher or when multiple symptoms overlap. The aim is to understand what strategies work best when standard approaches are not enough for you. This helps specialists refine treatment plans for more challenging cases.
The overall goal is to ensure that effective treatment options are available for a wider range of patients, regardless of disease complexity. You will see that this reflects a broader shift towards more personalised and adaptable care. Instead of a one-size-fits-all approach, treatment is increasingly adjusted to your individual needs. Ultimately, this helps improve outcomes and ensures more consistent care for you, even in more difficult cases.
Treatment Goals Continue to Evolve
You will notice that conference discussions are increasingly focusing on how treatment success is defined in a broader and more meaningful way. Rather than looking only at skin clearance, specialists now consider how well your joints are controlled, how your symptoms affect daily life, and how you are functioning overall. This gives a more complete picture of what good treatment actually means for you. As a result, the idea of “success” in psoriasis and psoriatic arthritis care is becoming more patient-centred.
You will also hear that researchers are continuing to explore how these treatment goals should be measured and tracked over time. This includes developing better ways to assess not just clinical improvement, but also how you feel and cope in everyday situations. By expanding what is measured, specialists can better understand whether a treatment is truly helping you. This supports more balanced and realistic treatment planning.
This more comprehensive approach reflects a stronger focus on your real-life experience rather than just medical test results. You will see that quality of life, mobility, comfort, and overall wellbeing are now central to treatment discussions. Future strategies are likely to continue moving in this direction as care becomes more personalised. Ultimately, this ensures that treatment goals better reflect what matters most to you in daily life.
Lifestyle Factors Are Being Investigated
When you attend international conferences, you will notice increasing interest in how lifestyle factors may influence conditions like Psoriasis and associated joint involvement. Researchers are actively exploring how everyday habits and overall health can affect disease activity and symptom severity. While lifestyle changes are not considered a cure, they are increasingly recognised as part of a broader management approach.
- Growing research into lifestyle influences: You will often hear discussions around how factors such as weight, smoking, stress levels, and physical activity may influence how active your condition becomes. These factors are being studied to better understand their role in flare-ups and symptom control.
- Lifestyle does not directly cause the condition: It is important to understand that lifestyle factors do not directly cause psoriasis or related joint disease. However, they may contribute to how severe symptoms are or how frequently flare-ups occur, which is why they are still clinically relevant.
- Focus on modifiable health factors: You may find that clinicians encourage attention to areas you can influence, such as maintaining a healthy weight, reducing smoking, managing stress, and staying physically active. These changes can support overall wellbeing and potentially improve disease control.
- Supporting a more holistic approach to care: Conferences increasingly highlight the importance of looking beyond medication alone. By considering both medical treatment and lifestyle factors, your care becomes more comprehensive and personalised.
- Increasing emphasis in clinical discussions: Lifestyle topics are now commonly included in international meetings. This reflects a broader shift towards understanding how overall health and daily habits can support long-term disease management.
Overall, lifestyle factors are becoming an important part of the conversation in psoriasis care. While they are not the cause of the condition, they can play a meaningful role in supporting better overall health and more stable disease control.
Early Intervention Strategies Are Being Explored
You will notice that many conference sessions are now focusing on whether starting treatment earlier could improve your long-term outcomes. Researchers are increasingly interested in how quickly inflammation should be controlled once your symptoms first appear. The idea is that earlier action may help reduce the overall impact of the disease over time. As a result, early intervention has become one of the most actively discussed areas in current research.
You will also hear that specialists are studying how prompt treatment might influence the way your condition progresses. This includes looking at whether earlier control of inflammation can help reduce the risk of worsening symptoms in both your skin and joints. By treating sooner, doctors hope to limit long-term damage and improve overall disease control for you. These discussions are helping to build a stronger evidence base for future care.
Conference presentations often explore how these findings could eventually shape future treatment recommendations. You will see that researchers are carefully evaluating which patients may benefit most from early intervention strategies. This could lead to changes in how quickly treatment is started after diagnosis. Ultimately, this area of research aims to improve long-term outcomes and support better disease management for you.
Biomarker Research Continues to Develop
You will notice that biomarkers are an increasingly important and exciting area of research in psoriasis and psoriatic arthritis. Scientists are exploring whether specific biological signals in your body could help predict how your disease may progress. This includes looking at whether certain markers can indicate how active your condition might become over time. As a result, biomarker research is gaining significant attention at international conferences.
You will also hear that researchers are investigating whether biomarkers could help predict how well you might respond to different treatments. This could eventually allow doctors to choose therapies that are more closely matched to your individual biological profile. By identifying the right treatment earlier, it may be possible to reduce the need for trial-and-error approaches. This would make your treatment journey more efficient and potentially more effective.
Conference discussions suggest that biomarker research could play an important role in supporting more personalised treatment decisions in the future. You will see that this is still an emerging field, and more evidence is needed before it becomes part of routine care. However, the potential benefits are significant, which is why it continues to attract strong interest. Ultimately, this area of research could help improve how your condition is managed in a more precise and targeted way.
Patient Education Is Being Prioritised
You will notice that patient education is becoming an increasingly important focus at psoriasis and psoriatic arthritis conferences. Speakers often highlight that when you understand your condition better, you are more likely to engage confidently with your treatment plan. This includes knowing what to expect from your symptoms, treatments, and long-term management. As a result, education is now seen as a key part of effective care rather than an optional extra.
You will also hear that improved education can support better treatment adherence and overall satisfaction. When you understand why a treatment is prescribed and how it works, you are more likely to follow it consistently. Conference sessions often explore different ways of improving communication between you and your healthcare team. This includes encouraging open discussions and shared decision-making during consultations.
Well-informed patients are often more confident in managing long-term conditions like psoriasis and psoriatic arthritis. You will see that education helps you feel more in control of your health and treatment choices. It also supports better understanding of flare-ups, triggers, and long-term expectations. Ultimately, patient education is becoming a central part of modern care, helping you achieve better outcomes and a more positive treatment experience.
Future Therapies Are a Major Area of Interest
When you attend international meetings, you will notice a strong focus on what the future of treatment might look like for conditions like Psoriasis. These discussions are important because they give you an idea of how research is shaping the next generation of therapies, especially for people who may also develop joint involvement.
- Exploring new treatment targets: You will often hear researchers discussing new biologic targets and signalling pathways involved in inflammation. These studies aim to identify more precise ways to control the disease and potentially improve outcomes.
- Development of more targeted therapies: A key area of interest is designing treatments that act more selectively on the immune system. The goal is to improve effectiveness while reducing unwanted side effects, giving you more refined treatment options in the future.
- Innovation in treatment approaches: Conferences frequently showcase early-stage research into novel therapies and delivery methods. These may include new drug classes or combination strategies that could enhance how the condition is managed long term.
- Potential benefits for skin and joint disease: Future treatments may not only improve skin symptoms but also help with joint-related issues in people who develop psoriatic arthritis. This broader approach is an important focus of ongoing research.
- Research-driven progress in dermatology: Overall, innovation continues to drive the field forward. You will see that much of the discussion at conferences is about where current research is heading and how it may translate into better care in the future.
In summary, future therapies remain a key area of interest because they offer the potential for more precise, effective, and comprehensive management of psoriasis and related conditions.
Conference Sessions Continue to Shape Patient Care
You will notice that psoriasis and psoriatic arthritis sessions remain some of the most important parts of international dermatology and rheumatology conferences. These sessions bring together experts to share new research, discuss treatment developments, and improve understanding of how these closely linked conditions affect you. This creates a space where knowledge can be exchanged and refined in a meaningful way. As a result, these meetings play a key role in shaping modern clinical practice.
You will also hear that the overall message from recent conferences is that care is becoming more personalised, more collaborative, and more focused on long-term outcomes for you. Researchers are continuously working to improve how psoriasis and psoriatic arthritis are diagnosed, monitored, and treated together. This includes better coordination between specialists and a stronger focus on your individual needs. It reflects a shift towards more joined-up and patient-centred care.
The aim of these ongoing discussions is to ensure that both your skin and joint symptoms are managed as effectively as possible over time. You will see that new research continues to explore better ways of understanding disease progression and improving treatment strategies. Ultimately, conference findings help guide more informed decisions in everyday clinical practice. This ensures that your care continues to improve based on the latest evidence and expert insight.
FAQs:
1. Why are psoriasis and psoriatic arthritis discussed together at conferences?
They are closely linked conditions that often occur in the same patients. Conferences combine both topics to improve understanding of how skin and joint symptoms interact. This helps specialists develop more coordinated treatment approaches.
2. What is the connection between psoriasis and psoriatic arthritis?
Psoriasis is a skin condition, while psoriatic arthritis affects the joints, but both are driven by inflammation. Many patients with psoriasis may develop joint symptoms over time. Research continues to explore why this overlap happens.
3. What early signs of psoriatic arthritis should patients look for?
Common early signs include joint stiffness, swelling, pain, and reduced movement, especially in the morning. These symptoms may appear gradually and are sometimes overlooked. Early reporting can help prevent long-term joint damage.
4. Why is early diagnosis of psoriatic arthritis important?
Early diagnosis allows treatment to begin sooner, which may help reduce inflammation and protect joints. Delayed treatment can increase the risk of permanent joint damage. Conferences strongly emphasise early detection strategies.
5. What treatments are commonly discussed at conferences?
Biologic therapies are frequently highlighted because they target specific inflammatory pathways. These treatments can improve both skin and joint symptoms. Researchers continue to study their long-term effectiveness and safety.
6. How do biologics help with psoriasis and psoriatic arthritis?
Biologics work by blocking parts of the immune system that cause inflammation. This helps reduce skin plaques and joint pain. They are considered an important part of modern treatment strategies.
7. Why is collaboration between specialists important?
Dermatologists manage skin symptoms, while rheumatologists focus on joints. Working together ensures both conditions are treated effectively. This multidisciplinary approach improves patient outcomes.
8. What role does lifestyle play in these conditions?
Lifestyle factors like stress, weight, smoking and physical activity may influence disease severity. They do not cause psoriasis or psoriatic arthritis but can affect symptoms. A balanced lifestyle may support overall management.
9. What is personalised treatment in psoriasis care?
Personalised treatment means tailoring care based on your symptoms, disease severity, lifestyle and medical history. It ensures more effective and targeted management. Conferences increasingly promote this approach.
10. How are conferences improving future care for patients?
Conferences bring together research, clinical experience and new treatment data. This helps shape better diagnostic methods and treatment strategies. The result is more effective and patient-focused care over time.
Final Thoughts: Advancing Psoriasis and Psoriatic Arthritis Care Through Global Research
International conference sessions on psoriasis and psoriatic arthritis continue to play a key role in shaping how these conditions are understood and managed in clinical practice. The consistent focus on early diagnosis, biologic therapies and personalised treatment reflects a shift towards more proactive and patient-centred care. For you as a patient, this means that treatment approaches are becoming increasingly informed by the latest global research and real-world evidence.
One of the most important takeaways from these discussions is the growing recognition that psoriasis and psoriatic arthritis are part of a connected disease spectrum. This has encouraged closer collaboration between dermatology and rheumatology specialists, helping ensure that both skin and joint symptoms are addressed together. As research continues to evolve, earlier detection and more tailored treatment strategies are likely to further improve long-term outcomes. If you’re considering psoriasis treatment in London, contact us at London Dermatology Centre to book a consultation with one of our specialists.
References:
- Behlock, Y., Gavan, S.P., Graier, T., Guevara, B.E., He, J., Giles, R.H., Wright, A.K., Ashcroft, D.M., Lim, H.W., De La Cruz, C., French, L.E., Foley, P., Lwin, S., Griffiths, C.E.M. and Van de Kerkhof, P.C.M. (2026) The role of biosimilars in enhancing global access to psoriasis treatment. Journal of Investigative Dermatology. https://www.sciencedirect.com/science/article/pii/S0022202X26010444
- Yee, S., Spatholt, D. and Harris, J. (2026) Psoriasis Today: Advanced Treatments, Comorbidities, and Personalized Care Approaches, Physician Assistant Clinics, 11(3), pp. 427-440. https://www.sciencedirect.com/science/article/abs/pii/S2405799126000071
- Zou, J., Huang, G., Hu, C., Yan, J., Zhang, F., Shi, H., Yuan, X., Fu, J. & Gong, L. (2021) Moxibustion therapy for treating psoriasis vulgaris: a protocol for systematic review and meta-analysis. Medicine (Baltimore), 100(12), e25250. https://pmc.ncbi.nlm.nih.gov/articles/PMC9281951/
- Luengas-Martinez, A., Paus, R. & Young, H.S. (2022) Antivascular endothelial growth factor-A therapy: a novel personalized treatment approach for psoriasis. British Journal of Dermatology, 186(5), pp. 782-791. https://pmc.ncbi.nlm.nih.gov/articles/PMC9313866/
- Wu, R., Zhao, L., Wu, Z., Liu, X., Li, J., Wang, T. & Zhang, L. (2024) Psoriasis and gut microbiota: A Mendelian randomization study. Journal of Cellular and Molecular Medicine, 28, e18023. https://pubmed.ncbi.nlm.nih.gov/39153596/